Kilcullen Niamh, Viswanathan Karthik, Das Rajiv, Morrell Christine, Farrin Amanda, Barth Julian H, Hall Alistair S
Coronary Artery Disease Clinical Research Network Group, Leeds Institute for Genetic, Health & Therapeutics, Leeds, United Kingdom.
J Am Coll Cardiol. 2007 Nov 20;50(21):2061-7. doi: 10.1016/j.jacc.2007.08.021. Epub 2007 Nov 5.
Our aim was to determine if a high-performance assay for heart-type fatty acid-binding protein (H-FABP) has a role in predicting all-cause mortality after acute coronary syndrome (ACS).
Heart-type fatty acid-binding protein is released into the circulation following myocardial ischemia and necrosis and therefore may be of value to physicians when caring for patients admitted to hospital with a clinical diagnosis of ACS.
This was a prospective observational study with a follow-up of 12 months. The H-FABP was measured 12 to 24 h after onset of symptoms in 1,448 patients admitted to hospital with ACS. The main outcome measure was all-cause mortality 1 year after index hospital admission. Multivariable analyses were conducted using the well validated GRACE (Global Registry of Acute Coronary Events) variables together with troponin I and highly sensitive C-reactive protein (hs-CRP).
After 12 months of follow-up, 296 patients had died. Multivariable analysis demonstrated that H-FABP quartiles were strongly predictive of outcome: Q1 hazard ratio (HR) 1.0; Q2 HR 2.32 (95% confidence interval [CI] 1.25 to 4.30; p = 0.007); Q3 HR 3.17 (95% CI 1.73 to 5.82; p < 0.001); Q4 HR 4.88 (95% CI 2.67 to 8.93; p < 0.001). The crude all-cause 1-year mortality for unstable angina patients with H-FABP <5.8 microg/l was 2.1% compared with 22.9% for patients above this cutoff. The adjusted all-cause mortality HR in this group was 11.35 (95% CI 2.00 to 64.34; p = 0.006).
Heart-type fatty acid-binding protein predicts long-term mortality after ACS and identifies high-risk patients in a manner that is additive to the GRACE clinical risk factors, troponin, and hs-CRP, possibly as a result of identifying the occurrence of myocardial ischemia with or without necrosis.
我们的目的是确定一种用于检测心脏型脂肪酸结合蛋白(H-FABP)的高性能检测方法在预测急性冠状动脉综合征(ACS)后全因死亡率方面是否具有作用。
心脏型脂肪酸结合蛋白在心肌缺血和坏死后释放入循环系统,因此对于临床诊断为ACS而入院治疗的患者,医生在护理时它可能具有价值。
这是一项为期12个月的前瞻性观察性研究。对1448例因ACS入院的患者在症状发作后12至24小时测量H-FABP。主要结局指标是首次入院后1年的全因死亡率。使用经过充分验证的GRACE(急性冠状动脉事件全球注册)变量以及肌钙蛋白I和高敏C反应蛋白(hs-CRP)进行多变量分析。
随访12个月后,有296例患者死亡。多变量分析表明,H-FABP四分位数对结局有很强的预测性:第一四分位数风险比(HR)为1.0;第二四分位数HR为2.32(95%置信区间[CI]为1.25至4.30;p = 0.007);第三四分位数HR为3.17(95%CI为1.73至5.82;p < 0.001);第四四分位数HR为4.88(95%CI为2.67至8.93;p < 0.001)。H-FABP<5.8微克/升的不稳定型心绞痛患者1年全因粗死亡率为2.1%,而高于此临界值的患者为22.9%。该组调整后的全因死亡率HR为11.35(95%CI为2.00至64.34;p = 0.006)。
心脏型脂肪酸结合蛋白可预测ACS后的长期死亡率,并能识别出高危患者,其方式可补充GRACE临床风险因素、肌钙蛋白和hs-CRP,这可能是由于识别了有无坏死的心肌缺血的发生。